Short ReportEfficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection

BackgroundThere are only limited data on sofosbuvir-based treatment regimens in hepatitis C virus (HCV) genotype 4-infected patients.AimsTo evaluate safety and efficacy of sofosbuvir-based triple-therapy in HCV genotype 4 infection.MethodsAll HCV genotype 4-infected patients who started sofosbuvir-based triple-therapy at our two centres between January and June 2014 were prospectively included (N = 24) and compared to genotype 4 patients treated with peginterferon/ribavirin between January 2001 and December 2012 (N = 63).ResultsThe demographics in the sofosbuvir group and the controls were comparable (males 87.5% and 82.5%; mean age 46.7 ± 9.0 years and 42.0 ± 9.8 years, respectively). Sustained virological response was achieved in 83.3% in the sofosbuvir group and in 47.6% of controls (P = 0.003). Fatigue (P = 0.007), flu-like (P = 0.015), gastrointestinal (P < 0.001), dermatologic (P < 0.001) and psychiatric symptoms (P = 0.022) were more common in the control group.ConclusionsIn our real-life cohort, sofosbuvir-based triple therapy confirmed its high efficacy and safety for chronic genotype 4 hepatitis C.